Imiquimod: Newer Perspectives to an Old Drug

Author:

Gupta Sonali1,Agarwal Pooja1,Baxi Kalgi1,Nyati Abhishek2

Affiliation:

1. Department of Dermatology, Smt. Nathiba Hargovandas Lakhmichand (NHL) Medical College, Ahmedabad, Gujarat, India,

2. Department of Oncology, Byramjee Jeejeebhoy Medical College (BJMC), Ahmedabad, Gujarat, India,

Abstract

Imiquimod is a topical age-old drug belonging to the imidazoquinolones class which acts by modulating the immune system. It has been approved by the US Food and Drug Administration for treating external genital and perianal warts, actinic keratoses and superficial basal cell carcinoma. Along with these, there have been a large number of diseases for which the drug has played a beneficial role with a good safety profile.

Publisher

Scientific Scholar

Reference28 articles.

1. Imiquimod: A Potential Role in Dermatology?;Eedy;Br J Dermatol,2002

2. Imiquimod: Unexpected Killer;Leverkus;J Invest Dermatol,2004

3. Therapeutic Response of Basal Cell Carcinoma to the Immune Response Modifier Imiquimod 5% Cream;Beutner;J Am Acad Dermatol,1999

4. Imiquimod 5 Percent Cream and the Treatment of Cutaneous Malignancy;Navi;Dermatol Online J,2004

5. Safety, Efficacy, and Recurrence Rates of Imiquimod Cream 5% for Treatment of Anogenital Warts;Diamantis;Skin Ther Lett,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3